Celcuity Reports Third Quarter 2026 Non-GAAP EPS Beat
Celcuity Inc. (CELC) reported third quarter 2026 financial results, highlighting a Non-GAAP earnings per share (EPS) of -$1.21, which exceeded analyst expectations by $0.32. Despite the earnings beat, the company saw an increase in cash burn, with net cash used in operating activities rising to $66.2 million compared to $44.8 million in the prior year period. The company continues to transition its focus toward the commercialization of REVTORPYK, which has demonstrated efficacy in boosting progression-free survival for breast cancer patients. While clinical evidence remains strong, the market reaction reflected volatility as investors weigh improved earnings against increased operational spending.
Tickers: $CELC
Topics: breast cancer treatment cash flow earnings beat non-GAAP EPS